192 results
8-K
EX-99.1
SYRE
Spyre Therapeutics Inc.
15 May 24
Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
7:40am
the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform
8-K
EX-99.1
SYRE
Spyre Therapeutics Inc.
9 May 24
Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:11pm
"forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All
POS AM
SYRE
Spyre Therapeutics Inc.
26 Mar 24
Prospectus update (post-effective amendment)
6:30pm
anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation … and fraud litigation, reputational harm, and other consequences.
Governments outside the United States tend to impose strict price controls, which
424B3
djwkqsn
18 Mar 24
Prospectus supplement
4:06pm
8-K
EX-10.1
8531tmm7somq9i6ei
18 Mar 24
Spyre Therapeutics Announces $180 Million Private Placement
8:31am
8-K
EX-99.1
r4gst3bm
18 Mar 24
Spyre Therapeutics Announces $180 Million Private Placement
8:31am
POS AM
h28071lib0
14 Mar 24
Prospectus update (post-effective amendment)
4:12pm
POS AM
boqxco432 rx246k0
5 Mar 24
Prospectus update (post-effective amendment)
5:15pm
8-K
EX-99.1
8jd3rkcogk7
29 Feb 24
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4:14pm
424B3
k5p24nppfh832wm
6 Feb 24
Prospectus supplement
9:37pm
8-K
EX-10.1
onc7be4 lgkahzs
5 Feb 24
Entry into a Material Definitive Agreement
7:36am